BiologicsHospitalsTop Stories

BONESUPPORT signs distribution agreement with OrthoPediatrics

 January 13, 2022

Lund, Sweden, 15:30 CET, 22-01-13 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has entered into a distribution agreement with OrthoPediatrics Corp., a leader in the orthopedic pediatric market, to distribute CERAMENT® BONE VOID FILLER (BVF) to pediatric hospitals within the United States. The contract extends BONESUPPORT’s market access further as it provides CERAMENT BVF access to OrthoPediatrics’ network of 250 pediatric hospitals.    

In the US, CERAMENT BVF is indicated for use in pediatric patients ages 9 years and older.

Under the terms of the 3-year agreement, OrthoPediatrics will employ its pediatric expertise and infrastructure to promote and distribute CERAMENT BVF within its network of orthopedic pediatric surgeons operating at more than 250 children’s hospitals across the country.

“OrthoPediatrics has demonstrated a strong leadership position in a short period of time, and we are thrilled to enter into this partnership which represents a strategic expansion for CERAMENT into a previously unpenetrated network of hospitals,” said Emil Billbäck, CEO of BONESUPPORT.  

“High quality bone graft substitutes are an essential component of orthopedic pediatric procedures. CERAMENT strengthens the OrthoPediatric portfolio, giving our customers access to what we believe is the best bone graft substitute on the market,” said Greg Odle, Executive Vice President of OrthoPediatrics.

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 36 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 45 countries outside the United States. For more information, please visit www.orthopediatrics.com.

For more information contact:

BONESUPPORT AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 181 million in 2020. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button